Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Acta Cardiol ; 78(1): 55-63, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-34979883

RESUMO

BACKGROUND: Distal transradial access (dTRA) as a refinement of the conventional transradial access (TRA) has advantages in terms of risk of radial artery occlusion (RAO). In order to evaluate the real-world feasibility and safety of dTRA as the default access site for routine coronary angiography (CAG) and percutaneous coronary intervention (PCI) in a Latin-American centre, this prospective observational registry was conducted. METHODS: Consecutive patients with a prior assessment for CAG and/or PCI were enrolled in this single-centre prospective registry from October 2018 to March 2019. The primary endpoints were the success rate of CAG and PCI. Secondary endpoints included the success rate of puncture of the distal radial artery, complications at the puncture site and puncture time. RESULTS: The success rates of CAG and PCI were 100% (155/155) and 97% (69/71), respectively. Puncture time and fluoroscopic time were 52 ± 19 seconds and 16.3 ± 35.4 minutes, respectively. Haemostasis time was 142 ± 45 min. A total of 19 (12.5%) puncture site complications occurred, including 18 (11.6%) minor haematomas and one (0.6%) arterial perforation, in which the artery was patent at the one-month follow-up. Five patients complained of left thumb numbness at a one-month follow-up. No distal radial artery occlusion, pseudoaneurysm, or arteriovenous fistula occurred. CONCLUSIONS: The success and complication rates of ldTRA support the feasibility and safety of this procedure using the appropriate materials in previously selected patients.


Assuntos
Arteriopatias Oclusivas , Intervenção Coronária Percutânea , Humanos , Angiografia Coronária/efeitos adversos , Angiografia Coronária/métodos , Intervenção Coronária Percutânea/efeitos adversos , Intervenção Coronária Percutânea/métodos , Estudos Prospectivos , Estudos de Viabilidade , Artéria Radial , Resultado do Tratamento
2.
Rev. mex. cardiol ; 29(2): 102-111, Apr.-Jun. 2018. graf
Artigo em Inglês | LILACS | ID: biblio-1020708

RESUMO

Abstract: Background: Aortic stenosis is the most common valvular heart disease worldwide. The prognosis is adverse without a valve replacement. Transcatheter aortic valve implantation (TAVI) has proven to be an effective treatment in high-surgical risk patients. Recent trials have highlighted the non-inferiority of TAVI compared with open surgery in patients with intermediate surgical risk. Case report: A 76-year-old man with severe aortic stenosis and intermediate surgical risk (STS-PROM 4.8%) who underwent TAVI with no complications. Results: Hospital discharge was decided five days after the procedure and continued outpatient follow-up. After two years remains in NYHA functional class I with a normofunctional percutaneous prosthesis. Conclusion: As this clinical case shows, TAVI has proven to be an effective treatment in patients with aortic stenosis and intermediate surgical risk. This is the first experience in this type of patients reported in our country.(AU)


Resumen: Antecedentes: La estenosis aórtica es la valvulopatía más común en todo el mundo. El pronóstico es sombrío sin reemplazo valvular. La implantación valvular aórtica transcatéter (TAVI) ha demostrado ser un tratamiento eficaz en pacientes de alto riesgo quirúrgico. Ensayos muy recientes destacaron la no-inferioridad de TAVI en comparación con la cirugía abierta en pacientes con riesgo quirúrgico intermedio. Caso clínico: Se presenta un hombre de 76 años de edad con estenosis aórtica severa y riesgo quirúrgico intermedio (STS-PROM 4.8%), al que se realiza TAVI sin complicaciones. Resultados: El alta hospitalaria se decide cinco días después del procedimiento para continuar el seguimiento ambulatorio. Después de dos años, el seguimiento permanece en la clase funcional I de la NYHA con una prótesis percutánea normofuncional. Conclusión: Como muestra este caso clínico, TAVI ha demostrado ser un tratamiento eficaz en pacientes de riesgo quirúrgico intermedio. Ésta es la primera experiencia en el uso de esta tecnología en este tipo de pacientes reportada en nuestro país.(AU)


Assuntos
Humanos , Masculino , Estenose da Valva Aórtica/cirurgia , Substituição da Valva Aórtica Transcateter/instrumentação , Doenças das Valvas Cardíacas/fisiopatologia , Medição de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...